Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 2/20 | 1.00 |
| ▸ | GPR183 | P32249 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CCR1 | P32246 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10300777 | 1.00 | F2R (1.00) | F2RGPR183MAPTL3MBTL1CCR1 | |
| SCHEMBL2903103 | 0.90 | F2R (0.82) | F2RGPR183MAPTL3MBTL1CCR1 | |
| SCHEMBL10300780 | 0.90 | F2R (0.82) | F2RGPR183MAPTL3MBTL1MEN1 | |
| SCHEMBL2903087 | 0.90 | F2R (0.81) | F2RGPR183MAPTL3MBTL1CCR1 | |
| SCHEMBL2909986 | 0.89 | F2R (0.80) | F2RGPR183CCR1MEN1KMT2A | |
| SCHEMBL2905717 | 0.89 | F2R (0.80) | F2RGPR183MAPTL3MBTL1CCR1 | |
| SCHEMBL2909314 | 0.89 | F2R (0.80) | F2RGPR183MAPTL3MBTL1CCR1 | |
| SCHEMBL2906392 | 0.88 | F2R (0.79) | F2RGPR183MAPTL3MBTL1MEN1 | |
| SCHEMBL2906158 | 0.87 | F2R (0.77) | F2RGPR183CCR1MEN1KMT2A | |
| SCHEMBL2908215 | 0.85 | F2R (0.74) | F2RGPR183MAPTL3MBTL1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | PIERRE FABRE MEDICAMENT (FR) | 2019-04-23 | — | — | US | claimed |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2018-11-01 | — | — | US | claimed |
| US-9980970-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | PIERRE FABRE MEDICAMENT (FR) | 2018-05-29 | — | — | US | claimed |
| EP-3082818-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | Pierre Fabre Médicament (FR) | 2016-10-26 | — | — | EP | claimed |
| US-20160287603-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2016-10-06 | — | — | US | claimed |
| WO-2016066789-A1 | USE OF PAR-1 ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF PELVIC-PERINEAL FUNCTIONAL DISORDERS | PIERRE FABRE MEDICAMENT (FR) | 2016-05-06 | — | — | WO | claimed |
| WO-2015090705-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2015-06-25 | — | — | WO | claimed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | claimed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | claimed |
| EP-2041104-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | Pierre Fabre Medicament (FR) | 2009-04-01 | — | — | EP | claimed |
| WO-2007147824-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | claimed |
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | PIERRE FABRE MEDICAMENT (FR) | 2019-04-23 | — | — | US | disclosed |
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | PIERRE FABRE MEDICAMENT (FR) | 2019-04-23 | — | — | US | disclosed |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2018-11-01 | — | — | US | disclosed |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | PIERRE FABRE MEDICAMENT (FR) | 2018-11-01 | — | — | US | disclosed |
| US-8217046-B2 | Cinnamoyl-piperazine derivatives and their use as PAR-1 antagonists | PIERRE FABRE MEDICAMENT (FR) | 2012-07-10 | — | — | US | disclosed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2041104-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | Pierre Fabre Medicament (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007147824-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | F2R 1/4885GPR183 891/4885MAPT 4777/4885 |
| US-20160287603-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | F2R, F2RL1, SERPINB1 | F2R 1/4885GPR183 945/4885MAPT 4226/4885 |
| US-10265322-B2 | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | F2R, F2RL1, SERPINB1 | F2R 1/4885GPR183 945/4885MAPT 4226/4885 |
| US-20180311253-A1 | USE OF PAR-1 ANTAGONISTS FOR PREVENTING AND/OR TREATING PELVI-PERINEAL FUNCTIONAL PATHOLOGICAL CONDITIONS | F2R, F2RL1, SERPINB1 | F2R 1/4885GPR183 945/4885MAPT 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.